Plasma exchange is the mainstay of treatment for acquired TTP, to remove the autoantibody against ADAMTS13 and the ultra-large vWF, while replacing the missing protease in the patient [1, 2, 4, 11]. The gene discussed is VWF; the disease is thrombotic thrombocytopenic purpura.